This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.
In your application messsage, please share your background and what you can contribute to the group.
Company Overview and News
KUALA LUMPUR (July 12): The FBM KLCI remained presured at mid-morning today, tracking regional markets as market sentiment stayed tepid with the spectre of a U.S.-China trade war still hanging over global markets.
HLFBF 7073 PBLOF 7113 4065 BATS TPGVF 4162 1295 7153 2089 KLKBY 3867 6139 7668 HRGHY UPBMF 1082 5168 0131 TGLVY 5139 2445 5216 0026 0900 1899 5819
KUALA LUMPUR (July 6): The FBM KLCI fell 0.77% at midday break as regional markets slumped, as U.S. tariffs against China took effect this afternoon.
PBLOF UPBMF 4065 6399 5681 1295 2089 7055 7154 5255 7277 CIMDF KLKBY 5139 1023 2445 0900 8613 0026 6888 2216 AXXTF
KUALA LUMPUR (July 6): The FBM KLCI fell 0.37% art mid-morning today, dragged by index-linked banking stocks against the backdrop of mixed regional markets.
MLYBY MLYNF UPBMF 4065 BATS 4162 2089 7055 7154 5255 CIMDF 1155 5139 1023 0900 0026 6888 5819 AXXTF
KUALA LUMPUR (July 5): The FBM KLCI turned negative at midday break today in tandem with most regional markets, on investors’ anxiety ahead of the Friday deadline for additional U.S. tariffs on Chinese products.
PBLOF MLYBY SPMXF MLYNF UPBMF BATS 4162 1163 1295 2089 9334 0023 1155 5139 SPMXY 3883 3301 0900 0026 1899 2836 3719
KUALA LUMPUR (July 4): The FBM KLCI pared some of its gains at mid-morning today in line with the shaky regional markets, as mounting worries of an escalating U.S.-China trade spat kept global investors on tenterhooks.
7084 4065 BATS 4162 1163 7374 7055 0120 KLKBY 5139 2445 4863 3867 0037 0900 0026 MYTEF 3719
KUALA LUMPUR (July 2): The FBM KLCI fell 0.47% at midday break today, as latest data showed business conditions across Malaysia’s manufacturing sector deteriorating, albeit at a slower pace in June.
HLFBF PBLOF 7113 7036 TPGVF 1295 7077 9334 DKSHY 5347 3301 8613 TNABY 5908 HRGHY SPMXF 1082 5681 5168 1481 TGLVY 5139 4588 SPMXY 0900 5819 TNABF DKSHF
AEON Credit Service Bhd (June 29, RM14.40) Maintain buy with a higher target price (TP) of RM15.40: AEON Credit’s (ACSM) first quarter for financial ended May 31, 2019 (1QFY19) earnings climbed 30.9% year-on-year (y-o-y) higher to RM99.2 million. The result was 32.3% and 31.2% of our and consensus estimates, which was slightly higher.
KUALA LUMPUR (July 2): The FBM KLCI remained subdued at mid-morning today after data showed business conditions across Malaysia’s manufacturing sector deteriorating albeit at a slower pace in June.
7052 PBLOF BATS 4162 1295 3794 2089 7077 5199 DKSHY KLKBY 3867 7206 HIPEF 5908 SPMXF UPBMF 8133 1481 5139 2445 4588 SPMXY 0026 0900 5819 DKSHF
KUALA LUMPUR (June 29): The FBM KLCI briefly crossed the 1,700-point level in the morning session today before paring some gains to close 1.8% higher at the break.
7251 MLYNF 7113 TPGVF 2089 5255 KLKBY 1023 5347 TNABY 2836 1929 HRGHY MLYBY UPBMF 5168 1481 CIMDF TGLVY 5139 1155 5216 2445 0900 TNABF
KUALA LUMPUR: AEON Credit Service (M) Bhd's net profit jumped 30.9% to RM99.24 million for the first financial quarter ended May 31, 2018 (1QFY19) from RM75.81 million a year ago, mainly due to an increase in financing receivables.
5139 0900 BSMAF 1818
KUALA LUMPUR (June 29): The FBM KLCI rose 1.38% at mid-morning today on 1H18 window-dressing activities, led by gains in Tenaga Nasional Bhd.
7172 7251 SPMXF 8621 7113 TPGVF 7765 5168 1481 5255 TGLVY 5139 KLKBY 2445 5216 SPMXY 5347 3026 0900 TNABY TNABF 1929 HRGHY
KUALA LUMPUR: Aeon Credit Service (M) Bhd shares got a boost on Friday after the company reported a 31% jump in net profit in the first quarter ended May 31.
5139 0900 BSMAF 1818
KUALA LUMPUR: Aeon Credit Service (M) Bhd , Icon Offshore Bhd , Mah Sing Group Bhd , United Malacca Bhd , Berjaya Corp (BCorp) and VS Industry Bhd are among the stocks to watch, according to JF Apex Research.
5139 0900 8583 5255 2593
KUALA LUMPUR (June 29): The FBM KLCI edged up in early trade this morning on some mild window dressing activities but gains may be limited as regional markets remained lacklustre.
7052 PBLOF SPMXF 7113 TPGVF 1295 5168 5014 TGLVY 5139 SPMXY 0900 MYPRY HRGHY
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...